Table 7.

Effects of EAF on serum cytokines and liver glycogen contents in T2D rats

Groups	TNF-α (pg/ml)	IL-6 (pg/ml)	IL-1β (pg/ml)	LG (mg/g tissue)
NDC	28.93 ± 6.48	89.17 ± 3.60	475.97 ± 20.64	15.57 ± 2.63
DC	122.60 ± 11.93a	171.67 ± 8.33a	1041.73 ± 43.71a	6.26 ± 0.67a
D + EAF25	76.77 ± 12.65b	116.94 ± 7.34b	839.76 ± 25.63b	10.11 ± 1.50
D + EAF50	59.10 ± 10.71b	97.78 ± 5.59b	590.97 ± 30.80b	12.67 ± 1.83
D + GLI	70.10 ± 4.00b	123.06 ± 10.18b	570.67 ± 31.71b	11.55 ± 1.82

TNFα tumor necrosis factor-alpha, IL-6 interleukin-6, IL-1β interleukin-1β, LG liver glycogen, NDC non-diabetic control, DC diabetic control, D + EAF25 diabetic rats treated with ethyl acetate fraction 25 mg/kg b.w., D + EAF50 diabetic rats treated with ethyl acetate fraction 50 mg/kg b.w., D + GLI diabetic rats treated with glibenclamide 10 mg/kg b.w. Results are considered significant when p < 0.05

^aCompared with NDC, ^bCompared with DC